Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

628 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: parekh s. J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3. J Hematol Oncol. 2022. PMID: 35978321 Free PMC article.
Adverse drug reaction: pomalidomide-induced liver injury.
Veluswamy RR, Ward SC, Yum K, Abramovitz RB, Isola LM, Jagannath S, Parekh S. Veluswamy RR, et al. Among authors: parekh s. Lancet. 2014 Jun 21;383(9935):2125-6. doi: 10.1016/S0140-6736(14)61030-8. Lancet. 2014. PMID: 24953475 No abstract available.
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS, Saroya BS, Stuart A, Shimko S, Evans J, Vinod Shah M, Sharma K, Leshchenko VV, Parekh S, Loughran TP Jr, Epner EM. Hasanali ZS, et al. Among authors: parekh s. Sci Transl Med. 2015 Jun 24;7(293):293ra102. doi: 10.1126/scitranslmed.aaa5079. Sci Transl Med. 2015. PMID: 26109102 Free PMC article. Clinical Trial.
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Laganà A, Perumal D, Melnekoff D, Readhead B, Kidd BA, Leshchenko V, Kuo PY, Keats J, DeRome M, Yesil J, Auclair D, Lonial S, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S. Laganà A, et al. Among authors: parekh s. Leukemia. 2018 Jan;32(1):120-130. doi: 10.1038/leu.2017.197. Epub 2017 Jun 23. Leukemia. 2018. PMID: 28642592
The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A. Lancman G, et al. Among authors: parekh s. Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Clin Adv Hematol Oncol. 2017. PMID: 29200420 Free PMC article. Review.
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.
Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. Chari A, et al. Among authors: parekh s. Blood Adv. 2017 Aug 21;1(19):1575-1583. doi: 10.1182/bloodadvances.2017007427. eCollection 2017 Aug 22. Blood Adv. 2017. PMID: 29296798 Free PMC article.
628 results